Yan Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yan Jin has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Feng Wang
Department of Animal Zoology, Kunming Medical University, Kunming, Yunnan, China
2 shared publications - Shuai Chen
Department of Orthopedics, The Affiliated Yan’an Hospital of Kunming Medical University, Kunming, Yunnan, China
2 shared publications - Yudong Gan
Department of Orthopedics, The Affiliated Yan’an Hospital of Kunming Medical University, Kunming, Yunnan, China
2 shared publications - Zenghui Liu
Department of Immunology, Mudanjiang Medical University, Mudanjiang, Heilongjiang, China
2 shared publications - Zhongzi Zhang
Department of Orthopedics, The Affiliated Yan’an Hospital of Kunming Medical University, Kunming, Yunnan, China
2 shared publications - Tong Wu
Department of Orthopedics, The Affiliated Yan’an Hospital of Kunming Medical University, Kunming, Yunnan, China
1 shared publication
Latest Publications
- Open Access
- 22 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (21) , e48948
Focus on CCL19: A Mendelian randomization study on genetic evidence of immune cells influencing osteoarthritis severity via inflammatory proteins
Osteoarthritis (OA) is a prevalent degenerative joint disorder whose pathogenesis involves immune-inflammatory regulation. Immune cells may influence OA progression by modulating inflammatory proteins; however, the underlying mechanisms remain inadequately understood. This study used Mendelian randomization (MR) analysis to investigate the causal effects of immune cells on OA. Additionally, it evaluated the mediating role of inflammatory proteins, particularly chemokine (C-C motif) ligand 19 (CCL19). Public genome-wide association study datasets were utilized, encompassing genetic data for 471 immune cell types, 91 inflammatory proteins, and OA (including generalized OA, knee osteoarthritis (KOA), and KOA with surgery). A bidirectional bivariate MR approach was employed to assess causal relationships between immune cells and OA; while mediating MR quantified the mediating effects of inflammatory proteins. Instrument selection criteria were P < 5 × 10 −8 and F > 10. The inverse variance weighted (IVW) method was the primary analytic technique, further validated through MR-Egger regression for robustness. MR analysis revealed that myeloid cell activation (e.g., CD33+ monocytes) positively correlated with OA risk (odds ratio [OR] = 1.014–1.049, P < .05), whereas regulatory T cell expression (e.g., CD4 on CD39+ activated Tregs) negatively correlated with risk (OR = 0.921–0.958, P < .05). The inflammatory protein CCL19 exhibited a protective effect against OA (OR = 0.876–0.924, P < .001), yet mediated an enhanced risk effect of immune cells on OA. Mediation analysis identified 5 significant pathways ( P < .05), with mediation proportions ranging from −13..5 to 20.5%, all showing CCL19 as a positive risk mediator. The findings suggest that immune cells influence the progression of OA through the mediation of CCL19, underscoring the critical role of the immune-inflammatory axis in the pathogenesis of OA. CCL19 may represent a promising therapeutic target, paving the way for the development of therapies aimed at inflammation modulation.
- 22 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (21) , e48948
Open AccessFocus on CCL19: A Mendelian randomization study on genetic evidence of immune cells influencing osteoarthritis severity via inflammatory proteins
Osteoarthritis (OA) is a prevalent degenerative joint disorder whose pathogenesis involves immune-inflammatory regulation. Immune cells may influence OA progression by modulating inflammatory proteins; however, the underlying mechanisms remain inadequately understood. This study used Mendelian randomization (MR) analysis to investigate the causal effects of immune cells on OA. Additionally, it evaluated the mediating role of inflammatory proteins, particularly chemokine (C-C motif) ligand 19 (CCL19). Public genome-wide association study datasets were utilized, encompassing genetic data for 471 immune cell types, 91 inflammatory proteins, and OA (including generalized OA, knee osteoarthritis (KOA), and KOA with surgery). A bidirectional bivariate MR approach was employed to assess causal relationships between immune cells and OA; while mediating MR quantified the mediating effects of inflammatory proteins. Instrument selection criteria were P < 5 × 10 −8 and F > 10. The inverse variance weighted (IVW) method was the primary analytic technique, further validated through MR-Egger regression for robustness. MR analysis revealed that myeloid cell activation (e.g., CD33+ monocytes) positively correlated with OA risk (odds ratio [OR] = 1.014–1.049, P < .05), whereas regulatory T cell expression (e.g., CD4 on CD39+ activated Tregs) negatively correlated with risk (OR = 0.921–0.958, P < .05). The inflammatory protein CCL19 exhibited a protective effect against OA (OR = 0.876–0.924, P < .001), yet mediated an enhanced risk effect of immune cells on OA. Mediation analysis identified 5 significant pathways ( P < .05), with mediation proportions ranging from −13..5 to 20.5%, all showing CCL19 as a positive risk mediator. The findings suggest that immune cells influence the progression of OA through the mediation of CCL19, underscoring the critical role of the immune-inflammatory axis in the pathogenesis of OA. CCL19 may represent a promising therapeutic target, paving the way for the development of therapies aimed at inflammation modulation.
- Open Access
- 6 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (6) , e47607
Uncovering metabolite-immune interactions in the pathogenesis of psoriatic arthritis: A 2-sample Mendelian randomization study
PsA is a chronic inflammatory joint condition associated with psoriasis, and its underlying mechanisms are not fully elucidated. Serum metabolites, as direct reflections of metabolic status, may influence disease progression by regulating immune cell function; however, the causal relationships and specific pathways require further investigation. The present investigation utilized a 2-sample bidirectional MR methodology, leveraging extensive pooled GWAS data to thoroughly evaluate the causal relationships between 1440 serum metabolites and PsA. Additionally, mediation MR analysis was performed to explore the possible mediating effects of 731 immune cell characteristics. In the primary analysis, inverse-variance weighted was employed, and this was further supported by various sensitivity analyses to confirm the reliability of the findings. The genetic method to infer causality analysis revealed significant positive causal associations between 10 serum metabolites and PsA risk, with quinolinate levels demonstrating the most significant correlation (OR = 1.56, 95% CI: 1.26–1.93); while 4 metabolites (e.g., citrate levels, OR = 0.74, 95% CI: 0.61–0.89) exhibited protective effects. Regarding immune cells, 6 cellular features (e.g., CD20 on B cells) were positively correlated with disease risk, whereas 5 features (primarily HLA-DR expression on monocyte subsets) showed negative correlations. Mediation analysis identified 3 significant pathways,the percentage of the effect explained by the mediator: N6,N6,N6-trimethyllysine levels mediated via B cells (CD20 on IgD+ CD38br), with a proportion of 33.2%; 1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) levels mediated through monocytes (HLA-DR on CD14− CD16−) with a 32.0% proportion; the unknown metabolite X-24736 also mediated 42.1% of the protective effect via the same monocyte phenotype. This study revealed that elevated amino acid-related metabolites and glycerophospholipids significantly increase PsA risk through immune cell effects. These are closely associated with PsA pathogenesis and may serve as potential biomarkers. The novel findings underscore metabolic-immune interactions as targets for biomarkers and therapies in PsA, advancing personalized medicine.
- 6 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (6) , e47607
Open AccessUncovering metabolite-immune interactions in the pathogenesis of psoriatic arthritis: A 2-sample Mendelian randomization study
PsA is a chronic inflammatory joint condition associated with psoriasis, and its underlying mechanisms are not fully elucidated. Serum metabolites, as direct reflections of metabolic status, may influence disease progression by regulating immune cell function; however, the causal relationships and specific pathways require further investigation. The present investigation utilized a 2-sample bidirectional MR methodology, leveraging extensive pooled GWAS data to thoroughly evaluate the causal relationships between 1440 serum metabolites and PsA. Additionally, mediation MR analysis was performed to explore the possible mediating effects of 731 immune cell characteristics. In the primary analysis, inverse-variance weighted was employed, and this was further supported by various sensitivity analyses to confirm the reliability of the findings. The genetic method to infer causality analysis revealed significant positive causal associations between 10 serum metabolites and PsA risk, with quinolinate levels demonstrating the most significant correlation (OR = 1.56, 95% CI: 1.26–1.93); while 4 metabolites (e.g., citrate levels, OR = 0.74, 95% CI: 0.61–0.89) exhibited protective effects. Regarding immune cells, 6 cellular features (e.g., CD20 on B cells) were positively correlated with disease risk, whereas 5 features (primarily HLA-DR expression on monocyte subsets) showed negative correlations. Mediation analysis identified 3 significant pathways,the percentage of the effect explained by the mediator: N6,N6,N6-trimethyllysine levels mediated via B cells (CD20 on IgD+ CD38br), with a proportion of 33.2%; 1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) levels mediated through monocytes (HLA-DR on CD14− CD16−) with a 32.0% proportion; the unknown metabolite X-24736 also mediated 42.1% of the protective effect via the same monocyte phenotype. This study revealed that elevated amino acid-related metabolites and glycerophospholipids significantly increase PsA risk through immune cell effects. These are closely associated with PsA pathogenesis and may serve as potential biomarkers. The novel findings underscore metabolic-immune interactions as targets for biomarkers and therapies in PsA, advancing personalized medicine.